OBJECTIVE:To compare economy among sodium valproate (VPA),topiramate (TPM) and dipheninum (DPH) in the treatment of epilepsy (EP). METHODS:Retrieved from ProQuest,PubMed,Springer,CJFD,VIP,Wanfang database,re-searches about economy among VPA,TPM and DPH in the treatment of EP were collected. TreeAge Pro 2011.1.0.12.1 software was used to establish Markov model,and cost-effectiveness ratios (CER) of them were calculated to evaluate their economy. RE-SULTS:CER of DPH,VPA,TPM were 29.99,2 664.52 and 6 657.25,in ascending order of DPH

Objective To assess the effect of recombinant human leukemia inhibitory factor (rhLIF) on mouse embryo development in vitro Methods Mice were randomly divided to three groups, one in vivo control (group Ⅰ) and two in vitro (group Ⅱ and Ⅲ) Mice were sacrificed at 116 120 hours (group Ⅰ) and 44-48 hours (group Ⅱ and Ⅲ) subsequent human chorionic gonadotropin (hCG) injection Two cell embryos (group Ⅱ and Ⅲ) and blastocysts (group Ⅰ) were obtained Embryos in group Ⅱwere cocultured with human tubal fluid (HTF) + 10% human serum and in group Ⅲ with HTF + 10% human serum+rhLIF (1 000 U/ml) The number of embryo in different stage was recorded and compared Results Embryo in four, eight cell and morula was noted in group Ⅱ and Ⅲ, 87 7% versus 91 2% and 75 0% versus 85 4% respectively There was no significant difference. However, further embryo development to the blastocyst, expanded blastocyst, and hatching blastocyst in group Ⅱ (48 1%, 32 1% and 18 4%) was lower than that in group Ⅲ (82 3%, 59 7% and 36 3%) There was no difference between blastocyst in group Ⅰ and group Ⅲ (86 0% vs 82 3%). Conclusion RhLIF does not provide obvious stimulation in early mouse embryo, however, rhLIF can promote the growth, differentiation, and hatching of preimplantion blastocyst